Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (vascular smooth muscle cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: vepalimomab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 135 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15356
Sealed predictions
- AOC3 in dopamine neurons, braak-0.16 (p 0.685) → -0.40 (p 0.281)receipt 15363
Swarm cases
receipt 15363: AOC3 in dopamine neurons, braak
- power
- full sample -0.33 (p 0.179, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.302, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.140, n 18). could be the mix.
- skeptic
- leave-one-out range -0.47 to -0.24, sign flips 0; without severely affected donors -0.33 (p 0.179, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AOC3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts